*Result*: Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA.
Original Publication: Auckland ; Philadelphia : Adis International, c1992-
NEWDIGS. Cell and gene therapy (CGT) pipeline deep dive. NEWDIGS at Tufts Medical Center for Biomedical System Design. Available from: https://newdigs.tuftsmedicalcenter.org/payingforcures/defining-disruption/cell-and-gene-therapy-products-and-pipeline/cgt-pipeline-deep-dive/#gsc.tab=0 . (Accessed 2 Jul 2025).
NEWDIGS. Cell and gene therapy (CGT) pipeline deep dive. NEWDIGS at Tufts Medical Center for Biomedical System Design. 2025. Available from: https://newdigs.tuftsmedicalcenter.org/payingforcures/defining-disruption/cell-and-gene-therapy-products-and-pipeline/cgt-pipeline-deep-dive/#gsc.tab=0 . (Accessed 1 Jul 2025).
US FDA. FDA to issue new Commissioner’s National Priority Vouchers to companies supporting U.S. national interests. US Food and Drug Administration. 2025. Available from: https://www.fda.gov/news-events/press-announcements/fda-issue-new-commissioners-national-priority-vouchers-companies-supporting-us-national-interests . (Accessed 1 Jul 2025).
Wagner TD, Sils B, Campbell FD. Cell and gene therapy: patient and caregiver odyssey. National Pharmaceutical Council. 2025. Available from: https://www.npcnow.org/sites/default/files/2025-01/Cell%20and%20Gene%20Therapy_Patient%20and%20Caregiver%20Odyssey_NPC%20White%20Paper.pdf . (Accessed 1 Jul 2025).
NEWDIGS. Cell and gene therapies (CGT) vs chronic therapies. NEWDIGS at Tufts Medical Center for Biomedical System Design. 2025. Available from: https://newdigs.tuftsmedicalcenter.org/payingforcures/defining-disruption/therapy-distinctiveness/#gsc.tab=0 . (Accessed 1 Jul 2025).
PhRMA. Cell and gene therapies. PhRMA. 2025. Available from: https://phrma.org/policy-issues/innovative-medicines/cell-gene-therapies . (Accessed 1 Jul 2025).
Council for Affordable Health Coverage. CAHC lauds Kymriah value-based arrangement: “A Win for Patients”. Council for Affordable Health Coverage. 2017. Available from: https://cahc.net/cahc-lauds-kymriah-value-based-arrangement-a-win-for-patients/ . (Accessed 1 Jul 2025).
Allen J, et al. Medicaid coverage practices for approved gene and cell therapies: existing barriers and proposed policy solutions. Mol Ther. 2023;29:513–21. https://doi.org/10.1016/j.omtm.2023.05.015 . (PMID: 10.1016/j.omtm.2023.05.015)
NEWDIGS. Selecting precision financing solutions. NEWDIGS at Tufts Medical Center for Biomedical System Design. 2025. Available from: https://newdigs.tuftsmedicalcenter.org/payingforcures/financing-therapies/selecting-precision-financing-solutions/#gsc.tab=0 . (Accessed 1 Jul 2025).
Allen J, Berry D, Cook F, et al. Medicaid coverage practices for approved gene and cell therapies: existing barriers and proposed policy solutions. Mol Ther. 2023;29:513–21. https://doi.org/10.1016/j.omtm.2023.05.015 . (PMID: 10.1016/j.omtm.2023.05.015)
Zemplényi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, et al. Innovative payment models for sickle-cell disease gene therapies in Medicaid: leveraging real-world data and insights from CMMI’s gene therapy access model. Pharmacoeconomics. 2025;43:583–94. (PMID: 10.1007/s40273-025-01474-33998260612011968)
Salzman R, Cook F, Hunt T, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 2018;26(12):2717–26. (PMID: 10.1016/j.ymthe.2018.10.017304147226277509)
DeMartino P, Kim DD, Trotter C, Carlson JJ, Pearson SD. A budget impact analysis of gene therapy for sickle cell disease: the Medicaid perspective. JAMA Pediatr. 2021;175(10):1053–5.
Zemplényi A, Homolya D, Inotai A. Using real-world data to inform value-based contracts for cell and gene therapies in Medicaid. Pharmacoeconomics. 2024;42(1):93–102.
AMCP Partnership Forum. Designing benefits and payment models for innovative high-investment medications. J Manag Care Spec Pharm. 2019;25(2):156–62. https://doi.org/10.18553/jmcp.2019.25.2.156 . (PMID: 10.18553/jmcp.2019.25.2.156)
Garrison LP, Kleinermans D. Is the world ready for gene therapy? Haemophilia. 2022;28(Suppl. 2):5–8. (PMID: 10.1111/hae.1443935318781)
Moradian R, Meshesha T, Trusheim M, Barlow JF. Payer and developer perspectives on alternative payment models. Expert Rev Pharmacoecon Outcomes Res. 2023;23(6):659–65. https://doi.org/10.1080/14737167.2023.2276374 . (PMID: 10.1080/14737167.2023.2276374)
Centers for Medicare & Medicaid Services. Cell and gene therapy (CGT) access model. Centers for Medicare & Medicaid Services. 2025. Available from: https://www.cms.gov/priorities/innovation/innovation-models/cgt . (Accessed 31 Oct 2025).
Goodman C, Berntorp E, Wong O, International Haemophilia Access Strategy Council. Alternative payment models for durable and potentially curative therapies: the case of gene therapy for haemophilia A. Haemophilia. 2022;28(Suppl. 2):27–34. (PMID: 10.1111/hae.1442535060645)
Bolous NS, Elalfy MS, Othman M, Hassan WA. Gene therapy and hemophilia: where do we go from here? J Blood Med. 2022;13:715–25. (PMID: 10.2147/JBM.S371438)
Driscoll D, Farnia S, Kefalas P, Maziarz RT. Concise review: the high cost of high tech medicine: planning ahead for market access. Stem Cell Transl Med. 2017;6(8):1723–8. (PMID: 10.1002/sctm.16-0487)
Moradian R, Meshesha T, Trusheim M, Barlow JF. Payer and developer perspectives on alternative payment models. Expert Rev Pharmacoecon Outcomes Res. 2023;23(6):659–65.
Centers for Medicare & Medicaid Services. Cell and gene therapy (CGT) access model. Centers for Medicare & Medicaid Services. 2025. Available from: https://www.cms.gov/priorities/innovation/innovation-models/cgt . (Accessed 1 Jul 2025).
McDonald M, Woodworth I. Cell and gene innovative payment models in the US: will they stick? ZS. 2024. Available from: https://www.zs.com/insights/innovative-payment-models-cell-and-gene-therapies . (Accessed 23 Jul 2025).
Orchard Therapeutics. Orchard Therapeutics outlines U.S. launch plans for Lenmeldy™ (atidarsagene autotemcel), the only approved therapy for children with early-onset metachromatic leukodystrophy. Orhcard Therapeutics. 2024. Available from: https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-outlines-us-launch-plans-lenmeldytm . (Accessed 23 Jul 2025).
Kansteiner F. Orchard sets new gene therapy price tag at $4.25M: the steepest of any drug. Fierce Pharma. 2024. Available from: https://www.fiercepharma.com/pharma/kyowa-kirins-orchard-sets-new-gene-therapy-price-tag-425m-steepest-any-drug-us . (Accessed 2 Jul 2025).
Phares S, Trusheim M, Emond SK, Pearson SD. Managing the challenges of paying for gene therapy: strategies for market action and policy reform. Institute for Clinical and Economic Review, NEWDIGS at Tufts Medical Center. 2024. Available from: https://icer.org/wp-content/uploads/2024/04/Managing-the-Challenges-of-Paying-for-Gene-Therapy-_-ICER-NEWDIGS-White-Paper-2024_final.pdf . (Accessed 1 Jul 2025).
bluebird bio, Inc. Bluebird bio announces first outcomes-based agreement with Medicaid for sickle cell disease gene therapy. bluebird bio, Inc. 2024. Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-first-outcomes-based-agreement-Medicaid . (Accessed 2 Jul 2025).
BioMarin. Reimbursement guide: Roctavian. 2023. Available from: https://hcp.biomarin.com/en-us/roctavian/wp-content/uploads/sites/3/2023/08/ROCTAVIAN-Reimbursement-Guide.pdf?v=0.85 . (Accessed 23 Jul 2025).
Munoz E. Vyjuvek: the first and only FDA-topical gene therapy. Employers Health. 2023. Available from: https://www.employershealthco.com/resource-center/articles/vyjuvek-the-first-and-only-fda-topical-gene-therapy/ . (Accessed 23 Jul 2025).
Taylor P. Abeona prices rare cell disorder gene therapy at $3.1m. pharmaphorum. 2025. Available from: https://pharmaphorum.com/news/abeona-prices-rare-cell-disorder-gene-therapy-31m . (Accessed 2 Jul 2025).
Odouard IC, Ballreich J, Socal MP. Medicaid spending and utilization of gene and RNA therapies for rare inherited conditions. Health Affairs Scholar. 2024;2(5):qxae051. https://doi.org/10.1093/haschl/qxae051 . (PMID: 10.1093/haschl/qxae0513877027011104525)
Dodda S, Hikmat Z, Sugarman R, Sheng C, Stuchiner A, Sporck M, Schroader B. US payer perceptions of innovative contracts with cell and gene therapies. AmerisourceBergen, AMCP 2023 Annual Meeting. 2023. Available from: https://www.amerisourcebergen.com/-/media/assets/xcenda/english/content-assets/conference-and-poster-presentations/2023/innovative-cgt-contracts_poster_amcp-2023.pdf . (Accessed 2 Jul 2025).
Bebinger M. Mass. Outlines deal for a $2 million drug: pay only if it works. wbur. 2020. Available from: https://www.wbur.org/news/2020/02/07/massachusetts-masshealth-zolgensma-cost-control . (Accessed 2 Jul 2025).
A Campaign for Transformative Therapies. Outcomes-based arrangements: sustainable financing for transformative therapies and a review of state activity. 2024. Available from: https://cahc.net/wp-content/uploads/2024/05/CTT-VBA-White-Paper-vApril2024FIN.pdf . (Accessed 12 Aug 2025).
Arizona Bioindustry Association. Curing the incurable: this gene therapy delivers. Available from: https://www.azbio.org/curing-the-incurable-this-gene-therapy-delivers . (Accessed 12 Aug 2025).
Novartis. AveXis announces innovative Zolgensma® gene therapy access programs for US payers and families. Novartis. 2019. Available from: https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families . (Accessed 2 Jul 2025).
bluebird bio, Inc. bluebird bio reports third quarter 2023 financial results and highlights operational progress. bluebird bio, Inc. 2023. Available from: https://www.sec.gov/Archives/edgar/data/1293971/000129397123000053/exhibit99120231107.htm . (Accessed 2 Jul 2025).
bluebird bio. bluebird bio announces U.S. commercial infrastructure to enable patient access to Zynteglo®, the first and only FDA-approved gene therapy for people with beta-thalassemia who require regular red blood cell transfusion. bluebird bio, Inc. 2022. Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-us-commercial-infrastructure-enable . (Accessed 2 Jul 2025).
Dodda S, Hikmat Z, Sugarman R, Sheng C, Stuchiner A, Sporck M, et al. US payer perceptions of innovative contracts with cell and gene therapies. AmerisourceBergen, AMCP 2023 Annual Meeting. 2023. Available from: https://www.amerisourcebergen.com/-/media/assets/xcenda/english/content-assets/conference-and-poster-presentations/2023/innovative-cgt-contracts_poster_amcp-2023.pdf . (Accessed 2 Jul 2025).
Congress.gov. Cash versus accrual basis of accounting: an introduction. Available from: https://www.congress.gov/crs-product/R43811 . (Accessed 9 Oct 2025).
Health Care Administrators Association. What is stop loss insurance? Available from: https://www.hcaa.org/page/selffundingstoploss . (Accessed 10 Oct 2025).
Spark Therapeutics. Spark Therapeutics announces first-of-their-kind programs to improve patient access to Luxturna™ (voretigene neparvovec-rzyl), a one-time gene therapy treatment. Spark Therapeutics, Inc. 2018. Available from: https://www.globenewswire.com/news-release/2018/01/03/1281548/0/en/Spark-Therapeutics-Announces-First-of-their-kind-Programs-to-Improve-Patient-Access-to-LUXTURNA-voretigene-neparvovec-rzyl-a-One-time-Gene-Therapy-Treatment.html . (Accessed 2 Jul 2025).
BioSpace. Spark Therapeutics announces first-of-their-kind programs to improve patient access to Luxturna (voretigene neparvovec-rzyl), a one-time gene therapy treatment. 2018. Available from: https://www.biospace.com/spark-therapeutics-announces-first-of-their-kind-programs-to-improve-patient-access-to-luxturna-voretigene-neparvovec-rzyl-a-one-time-gene-therapy-treatment . (Accessed 3 Jul 2025).
Wagner TD, Buelt L, Westrich K, Campbell JD. Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States. J Comp Eff Res. 2024. https://doi.org/10.57264/cer-2024-0098 . (PMID: 10.57264/cer-2024-00983956030611610046)
Synergie. About Synergie. Synergie Medication Collective. 2025. Available from: https://www.synergiecollective.com/ . (Accessed 2 Jul 2025).
Evio. How our solutions reduce high cost medication spend. Evio. 2025. Available from: https://www.evio.com/solutions#innovative-contracting-at-scale . (Accessed 2 Jul 2025).
Barlow J, Courtney MW. Payer perspectives on gene therapy reimbursement. Pharmaceutical Executive. 2020. Available from: https://www.pharmexec.com/view/payer-perspectives-gene-therapy-reimbursement . (Accessed 2 Jul 2025).
McDonald M, Woodworth I. Cell and gene innovative payment Models in the US: will they stick? ZS. 2024. Available from: www.zs.com/insights/innovative-payment-models-cell-and-gene-therapies . (Accessed 2 Jul 2025).
Wagner TD, Buelt L, Westrich K, Campbell JD. Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States. J Comp Eff Res. 2024;13(12):e240098. https://doi.org/10.57264/cer-2024-0098 . (PMID: 10.57264/cer-2024-00983956030611610046)
Berry D, Hickey C, Kahlman L, Long J, Markus C, McCombs CK. Ensuring patient access to gene therapies for rare diseases: navigating reimbursement and coverage challenges. Am Soc Gene Cell Ther. 2025. Available from: https://www.asgct.org/advocacy/policy-statement-landing/2025/ensuring-patient-access-to-gene-therapies-for-rare# . (Accessed 2 Jul 2025).
US FDA. Food and Drug Administration Modernization Act of 1997. Available from: https://www.govinfo.gov/content/pkg/PLAW-105publ115/pdf/PLAW-105publ115.pdf . (Accessed 2 Jul 2025).
Centers for Medicare & Medicaid Services. Biden-Harris Administration takes next steps to increase access to sickle cell disease treatments. Centers for Medicare & Medicaid Services. 2024. Available from: https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-steps-increase-access-sickle-cell-disease-treatments . (Accessed 2 Jul 2025).
Centers for Medicare & Medicaid Services. CMS expands access to lifesaving gene therapies through innovative state agreements. Centers for Medicare & Medicaid Services. 2025. Available from: https://www.cms.gov/newsroom/press-releases/cms-expands-access-lifesaving-gene-therapies-through-innovative-state-agreements . (Accessed 31 Oct 2025).
*Further Information*
*Background and Objective: Over the last decade, payers in the USA have been exploring novel financing mechanisms for gene therapies (GTs). Our research objective was to assess the landscape of innovative contracts (ICs) between payers and manufacturers for GTs and identify barriers and opportunities for future contract development and implementation.
Methods: We used a multi-method approach including a targeted literature review and interviews. We developed a framework defining 'innovative contracts' as agreements using real-world outcomes that link to the total price paid for gene therapy, encompassing value-based pricing, outcome-based payments, and performance-based models between payers and manufacturers. We searched for published information about implementation of ICs for GTs in PubMed and government, industry, and research institutions from January 2014 to January 2025. We excluded any insights specific to ICs for non-GTs as well as those relevant to ex-US markets. We supplemented these findings with bibliographic searches. Semi-structured interviews with payers, manufacturers, and other diverse representatives from the GT financing ecosystem were conducted to validate and enrich the literature findings.
Results: The PubMed search yielded ten studies relevant to implementation of ICs. Gray literature included over 50 publications referencing active contracts, policy solutions, payer budget impact, and state Medicaid programs' innovative GT contracting. Information on manufacturer and payer contracts was publicly available for 10 of 14 gene therapies (71%). Of 16 identified GT contracts, eight used upfront payments with milestone-based rebates, two used performance-based installment payments, one offered upfront payment with a rebate or payment over 5 years, and five do not have publicly available details on the type of financial arrangement. Interviews (N = 15) suggested that barriers to ICs include a lack of mutual trust between payers and manufacturers, lack of data conveying the return on investment for innovative contracts, lack of a sufficient incentive for stakeholders to engage in contracting, perceived regulatory limitations (e.g., implications of Medicaid Best Price), and patient portability challenges. Some interviewees believed that ICs should be the standard for GTs, while others stated that ICs should only be pursued when they are expected to have a significant impact on timely patient access in the early launch period when payers are considering limited or no coverage. Interviewees indicated that policy changes may encourage future contracting negotiation and implementation.
Conclusions: Widespread uptake of ICs will require a multi-stakeholder collaboration to overcome common barriers, as a one-size-fits-all approach is insufficient for diverse stakeholder needs. Establishing industry-wide contracting principles and practices may help bridge differences in opinions and build trust between contracting parties, allow stakeholders to share lessons from early adopters, and support efficient contracting processes that promote consistent and equitable patient access to GTs while ensuring healthcare system sustainability.
(© 2025. The Author(s).)*
*Declarations. Conflicts of Interest/Competing Interests: Tyler D. Wagner, Jacqlyn W. Riposo, Kendra M. Gould, Jonathan D. Campbell, James T. Kenney, Claire M. Csenge, and Theresa Schmidt have no conflicts of interest that are directly relevant to content of this study. Ethics Approval: The interviews completed as part of this study received institutional review board exemption determination by Advarra Institutional Review Board (Pro00084698). Consent to Participate: Interview participants provided verbal consent to participate. Consent for Publication: Not applicable. Availability of Data and Material: Qualitative data including recordings and transcripts from interviews are retained on a secure online platform that can only be accessed by the study leads. Per the institutional review board requirement, all recordings and transcriptions will be destroyed within 12 months of study completion. A thematic summary of the interviews is available upon request. Code Availability: Not applicable. Authors’ Contributions: TDW: funding acquisition, conceptualization, methodology, writing (original draft preparation), review and editing. JWR: conceptualization, methodology, investigation, formal analysis, writing (original draft preparation), review and editing. KMG: project administration, conceptualization, methodology, investigation, formal analysis, writing (original draft preparation), review and editing. JDC: funding acquisition, conceptualization, methodology, supervision, review and editing. JTK: investigation, review and editing. CMC: investigation, writing (original draft preparation). TS: conceptualization, methodology, investigation, formal analysis, writing (original draft preparation), review and editing. All authors read and approved the final manuscript.*